Skip to main content
Top
Published in: Rheumatology International 9/2012

01-09-2012 | Original Article

Evaluation of apoptosis-related gene Fas (CD95) and FasL (CD178) polymorphisms in Iranian rheumatoid arthritis patients

Authors: Adel Mohammadzadeh, Ali Akbar Pourfathollah, Mohammad Taher Tahoori, Saeed Daneshmandi, Ladan Langroudi, Masoumeh Akhlaghi

Published in: Rheumatology International | Issue 9/2012

Login to get access

Abstract

Apoptosis signals are essential for establishing homeostasis and adequate immune response. Dysregulation of apoptosis-related genes in the immune system, which could be due to gene polymorphisms, conduct to autoimmune diseases including rheumatoid arthritis. In the current study, the apoptosis-related gene Fas_-670A>G, FasL_844C>T, and FasLIVS2nt_124A>G polymorphisms were genotyped in 120 Iranian patients with rheumatoid arthritis (RA) and 112 unrelated healthy controls using PCR–RFLP method. Among the 120 RA patients being heterozygous in the promoter region of Fas_-670A/G (OR 1.42,CI 0.92-1.52, P = 0.18) and FasL_-844C/T (OR 1.42, CI 0.92-1.52, P = 0.18) and homozygous in the minor allele for FasLIVS2nt_124G/G (OR 1.43, CI 0.76-1.81, P = 0.7), the frequency of these polymorphisms is higher in the cases than in controls and the elevated risk of RA were observed when the patient compared with controls, although this is not statistically significant.
Literature
1.
go back to reference Pope RM (2002) Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2:527–535PubMedCrossRef Pope RM (2002) Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2:527–535PubMedCrossRef
2.
go back to reference Hasunuma T, Kayagaki N, Asahara H et al (1997) Accumulation of soluble Fas in inflamed joints of patient with rheumatoid arthritis. Arthritis Reum 40:80–86CrossRef Hasunuma T, Kayagaki N, Asahara H et al (1997) Accumulation of soluble Fas in inflamed joints of patient with rheumatoid arthritis. Arthritis Reum 40:80–86CrossRef
3.
go back to reference Asahara H, Hasunuma T, Kubata T et al (1997) In situ expression of protooncogenes and Fas/Fas ligand in rheumatoid arthritis synovium. J Rheumatol 24:430–435PubMed Asahara H, Hasunuma T, Kubata T et al (1997) In situ expression of protooncogenes and Fas/Fas ligand in rheumatoid arthritis synovium. J Rheumatol 24:430–435PubMed
4.
go back to reference Cantwell MJ, Hua T, Zvaifler NJ, Kipps TJ (1997) Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum 40:1644–1652PubMedCrossRef Cantwell MJ, Hua T, Zvaifler NJ, Kipps TJ (1997) Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum 40:1644–1652PubMedCrossRef
5.
go back to reference Perlman H, Pagliari LJ, Liu H, Koch AE, Haines GK III, Pope RM (2001) Rheumatoid arthritis synovial macrophages express the Fas-associated death domain-like interleukin-1_-converting enzyme-inhibitory protein and are refractory to Fas-mediated apoptosis. Arthritis Rheum 44:21–30PubMedCrossRef Perlman H, Pagliari LJ, Liu H, Koch AE, Haines GK III, Pope RM (2001) Rheumatoid arthritis synovial macrophages express the Fas-associated death domain-like interleukin-1_-converting enzyme-inhibitory protein and are refractory to Fas-mediated apoptosis. Arthritis Rheum 44:21–30PubMedCrossRef
6.
go back to reference Catrina AI, Ulfgren AK, Lindblad S, Grondal L, Klareskog L (2002) Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis 61:934–936PubMedCrossRef Catrina AI, Ulfgren AK, Lindblad S, Grondal L, Klareskog L (2002) Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis 61:934–936PubMedCrossRef
7.
go back to reference Schedel J, Gay RE, Kuenzler P et al (2002) FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis. Arthritis Rheum 46:1512–1518PubMedCrossRef Schedel J, Gay RE, Kuenzler P et al (2002) FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis. Arthritis Rheum 46:1512–1518PubMedCrossRef
8.
go back to reference Zhang J, Bardos T, Mikecz K, Finnegan A, Glant TT (2001) Impaired Fas signaling pathway is involved in defective T cell apoptosis in autoimmune murine arthritis. J Immunol 166:4981–4986PubMed Zhang J, Bardos T, Mikecz K, Finnegan A, Glant TT (2001) Impaired Fas signaling pathway is involved in defective T cell apoptosis in autoimmune murine arthritis. J Immunol 166:4981–4986PubMed
9.
go back to reference Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169–1178PubMedCrossRef Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169–1178PubMedCrossRef
10.
go back to reference Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330PubMed Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330PubMed
11.
go back to reference Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, Cooke J, Xie F, Cooper GS, Kimberly RP (2003) A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170:132–138PubMed Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, Cooke J, Xie F, Cooper GS, Kimberly RP (2003) A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170:132–138PubMed
12.
go back to reference Bolstad AI, Wargelius A, Nakken B, Haga HJ, Jonsson R (2000) Fas and Fas ligand gene polymorphisms in primary Sjogren’s syndrome. J Rheumatol 27:2397–2405PubMed Bolstad AI, Wargelius A, Nakken B, Haga HJ, Jonsson R (2000) Fas and Fas ligand gene polymorphisms in primary Sjogren’s syndrome. J Rheumatol 27:2397–2405PubMed
13.
go back to reference Besma BHJ, Wijden M, Noureddine B, Sallouha G, Slim BA et al (2006) A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction. Cancer Lett 233:21–27CrossRef Besma BHJ, Wijden M, Noureddine B, Sallouha G, Slim BA et al (2006) A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction. Cancer Lett 233:21–27CrossRef
14.
go back to reference Stuck BJ, Pani MA, Besrour F et al (2003) Fas ligand gene polymorphisms are not associated with Hashimoto’s thyroiditis and Graves’ disease. Hum Immunol 64:285–289PubMedCrossRef Stuck BJ, Pani MA, Besrour F et al (2003) Fas ligand gene polymorphisms are not associated with Hashimoto’s thyroiditis and Graves’ disease. Hum Immunol 64:285–289PubMedCrossRef
15.
go back to reference Ogawa Y, Kuwahara H, Kimura T et al (2001) Therapeutic effect of anti-Fas antibody on a collagen induced arthritis model. J Rheumatol 28:950–955PubMed Ogawa Y, Kuwahara H, Kimura T et al (2001) Therapeutic effect of anti-Fas antibody on a collagen induced arthritis model. J Rheumatol 28:950–955PubMed
16.
go back to reference Guery L, Batteux F, Bessis N et al (2000) Expression of Fas ligand improves the effect of IL-4 in collagen-induced arthritis. Eur J Immunol 30:308–315PubMedCrossRef Guery L, Batteux F, Bessis N et al (2000) Expression of Fas ligand improves the effect of IL-4 in collagen-induced arthritis. Eur J Immunol 30:308–315PubMedCrossRef
17.
go back to reference Kim SH, Kim S, Oligino TJ, Robbins PD (2002) Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther 6:584–590PubMedCrossRef Kim SH, Kim S, Oligino TJ, Robbins PD (2002) Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther 6:584–590PubMedCrossRef
18.
go back to reference Catrina AI, Trollmo C, af Klint E et al (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52:61–72PubMedCrossRef Catrina AI, Trollmo C, af Klint E et al (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52:61–72PubMedCrossRef
19.
go back to reference Cohen PL, Eisenberg RA (1991) Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9:243–269PubMedCrossRef Cohen PL, Eisenberg RA (1991) Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9:243–269PubMedCrossRef
20.
go back to reference Das H, Koizumi T, Sugimoto T et al (2000) Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 82:1682–1688PubMedCrossRef Das H, Koizumi T, Sugimoto T et al (2000) Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 82:1682–1688PubMedCrossRef
21.
go back to reference Kanemitsu S et al (2002) A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 29:1183–1188PubMed Kanemitsu S et al (2002) A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 29:1183–1188PubMed
22.
go back to reference Huang QR et al (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34:577–582PubMedCrossRef Huang QR et al (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34:577–582PubMedCrossRef
23.
go back to reference Huang WX, Huang MP, Gomes MA, Hillert J (2000) Apoptosis mediator’s fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 55:928–934PubMedCrossRef Huang WX, Huang MP, Gomes MA, Hillert J (2000) Apoptosis mediator’s fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 55:928–934PubMedCrossRef
25.
go back to reference Shimonishi T, Isse K, Shibata F et al (2000) Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 32:761–769PubMedCrossRef Shimonishi T, Isse K, Shibata F et al (2000) Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 32:761–769PubMedCrossRef
Metadata
Title
Evaluation of apoptosis-related gene Fas (CD95) and FasL (CD178) polymorphisms in Iranian rheumatoid arthritis patients
Authors
Adel Mohammadzadeh
Ali Akbar Pourfathollah
Mohammad Taher Tahoori
Saeed Daneshmandi
Ladan Langroudi
Masoumeh Akhlaghi
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 9/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2065-x

Other articles of this Issue 9/2012

Rheumatology International 9/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.